Wealth Enhancement Advisory Services
TRDA icon

Wealth Enhancement Advisory Services’s Entrada Therapeutics TRDA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$80.8K Buy
14,608
+1,839
+14% +$12.8K ﹤0.01% 3971
2026
Q2 		$88.4K Buy
+12,769
New +$122K ﹤0.01% 3825

Other funds holding TRDA

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Wealth Enhancement Advisory Services's TRDA Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Entrada Therapeutics (TRDA) stake by 14% in Q3 2026, buying an estimated $12.8K and bringing the position to 14,608 shares worth $80.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3971.

Wealth Enhancement Advisory Services first reported a position in TRDA in Q2 2026 and has held it in 2 quarters since. The position peaked at $88.4K in Q2 2026. 8 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Wealth Enhancement Advisory Services held 14,608 shares of Entrada Therapeutics worth $80.8K as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 1,839 Entrada Therapeutics shares in Q3 2026, an estimated $12.8K.
  • Entrada Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3971 holding.
  • Wealth Enhancement Advisory Services first reported a position in Entrada Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Wealth Enhancement Advisory Services's Entrada Therapeutics position peaked at $88.4K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.